EUVIMEDEUVIMED entdecken
Open Access · CC BY 3.0

A Phase IIIb, Multicentre, Randomised, Parallel-Group, Placebo-Controlled, Double-Blind Study to Investigate the Efficacy and Safety of OROS Hydromorphone in Subjects with Moderate-to-Severe Chronic Pain Induced by Osteoarthritis of the Hip or the Knee

Jozef Vojtaššák, Jozef Vojtaššák, Adam Jacobs, Leonie Rynn, Sandra Waechter, Ute Richarz

Pain Research and Treatment · 2011

DOI: 10.1155/2011/239501 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pain Research and Treatment, 2011. Verfasst von Jozef Vojtaššák und 5 weiteren Autor:innen. Beteiligte Einrichtung: Orthos Paidion, 83263 Bratislava, Slovakia. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 3.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Opioid analgesics are included in treatment guidelines for the symptomatic management of osteoarthritis (OA). Starting with a low dose of opioid and slowly titrating to a higher dose may help avoid intolerable side effects.

Methods

Subjects aged ≥40 years, with moderate to severe pain induced by OA of the hip or knee not adequately controlled by previous non-steroidal anti-inflammatory drugs (NSAIDs) or paracetamol treatment, were enrolled. Subjects received OROS hydromorphone 4 mg or placebo once-daily. The dose was titrated every 3-4 days in case of unsatisfactory pain control during the 4-week titration phase. A 12 week maintenance phase followed. The primary efficacy endpoint was the change in “pain on average” measured on the Brief Pain Inventory (BPI) scale from baseline to the end of the maintenance phase.

Results

139 subjects received OROS hydromorphone and 149 subjects received placebo. All efficacy endpoints showed similar improvements from baseline to end of study in the 2 groups. The safety results were consistent with the safety profile of OROS hydromorphone. Conclusion .The study did not meet the primary endpoint; although many subjects' pain was not adequately controlled at inclusion, their pain may have improved with continued paracetamol or NSAID treatment.

Autor:innen und Institutionen

  • Orthos Paidion, 83263 Bratislava, Slovakia.

Zitieren

APA

Vojtaššák, J., Vojtaššák, J., Jacobs, A., Rynn, L., Waechter, S., & Richarz, U. (2011). A Phase IIIb, Multicentre, Randomised, Parallel-Group, Placebo-Controlled, Double-Blind Study to Investigate the Efficacy and Safety of OROS Hydromorphone in Subjects with Moderate-to-Severe Chronic Pain Induced by Osteoarthritis of the Hip or the Knee. Pain Research and Treatment. https://doi.org/10.1155/2011/239501

Vancouver

Vojtaššák J, Vojtaššák J, Jacobs A, Rynn L, Waechter S, Richarz U. A Phase IIIb, Multicentre, Randomised, Parallel-Group, Placebo-Controlled, Double-Blind Study to Investigate the Efficacy and Safety of OROS Hydromorphone in Subjects with Moderate-to-Severe Chronic Pain Induced by Osteoarthritis of the Hip or the Knee. Pain Research and Treatment. 2011. doi:10.1155/2011/239501

BibTeX
@article{Vojtak2011,
  author = {Vojtaššák, Jozef and Vojtaššák, Jozef and Jacobs, Adam and Rynn, Leonie and Waechter, Sandra and Richarz, Ute},
  title = {A Phase IIIb, Multicentre, Randomised, Parallel-Group, Placebo-Controlled, Double-Blind Study to Investigate the Efficacy and Safety of OROS Hydromorphone in Subjects with Moderate-to-Severe Chronic Pain Induced by Osteoarthritis of the Hip or the Knee},
  journal = {Pain Research and Treatment},
  year = {2011},
  doi = {10.1155/2011/239501}
}
Kostenlos starten →